Park Ha Biological Technology Co., Ltd. shares rise 2.49% premarket after Opus Genetics announces IRD gene therapy programs presentation.
ByAinvest
Thursday, Aug 28, 2025 4:56 am ET1min read
PHH--
Park Ha Biological Technology Co., Ltd. rose 2.49% in premarket trading. Opus Genetics, Inc. announced that it will present on its IRD gene therapy programs at the Ophthalmology Futures Forum in Paris, France on September 3, 2025. The company's Senior Vice President Clinical Development, Sally Tucker, Ph.D., will participate in a panel discussion titled "Gene & Cell Therapies for Rare & Common Retinal Diseases: Hype Vs Progress" and deliver a corporate presentation later that day.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet